Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
- Eli Lilly and Company's stock has seen an unexpected drop recently following disappointing developments in its Q3 results and more recently a lawsuit against the HRSA.
- While slowing sales growth for key drugs like Mounjaro and Zepbound might be a blip, it's worth watching out for developments going forward.
- The company also continues to be in the crosshairs with the government, having sued the HRSA recently for rejecting its payment method under the 304B program.
- As a result, despite a more attractive forward P/E ratio than even a couple of months ago, it's best to err on the side of caution right now.
Michael Vi
Pharmaceuticals stock Eli Lilly and Company (NYSE:LLY) is down by 23% since I last wrote about it in September. At the time, it appeared that the company could come out on top despite challenges related to
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
